engleski

The diagnostic potential of human epididymis protein 4 (HE4) and ROMA index in women with ovarian cancer

Introduction: Ovarian cancer which in Croatia is fifth in newly diagnosed cancer in women ; 440 newly diagnosed die 301 women. In recent years, the arguments are that the HE4, either by itself or in combination with CA 125 as part of the ROMA calculations far more reliable marker (no increases in endometriosis, cysts and non- gynecological malignancies). First time in Croatia examined the utility of HE4 and ROMA calculating the classification of ovarian tumors of other gynecological malignancies. Subjects and Methods: The study included 63 patients of Institute for tumors with preoperative findings demonstrated tumor mass in the pelvis of unknown etiology. In 20/63 women subsequent histopathologic diagnosis was confirmed ovarian cancer. HE4 and CA125 measurement were the Elecsys 2010 (Roche). The subjects were classified according to menopausal status, to the ROMA calculation formula is used. Results: Measured concentrations of HE4 in a group of women with ovarian cancer 131.7 (76.6-639.9) mg/mL was significantly higher than other gynecological malignancies 52.6 (48.1-62.2) mg/mL ; P<0.001. ROC analysis revealed 64.7% sensitivity and 90.5% specificity with cutt-of 95.62 mg/mL ; AUC of 80.3% for the HE4 and 70.6% sensitivity and 88.9% specificity with the cutt-of 34.1 mg/mL ; AUC of 82.2% for the calculation of the ROMA in distinguishing ovarian cancer from other cancers. Conclusion: The results confirm literature data of the usability of HE4 and ROMA calculation. Confirmed the relevance and usefulness of preoperative findings clinician operator to be doing just about ovarian cancer. Incomparably smaller number of false positive results in comparison with CA125 makes HE4 almost ideal organ specific tumor marker. Calculation HE4 with CA125 within ROMA calculation increases the sensitivity with only a slight reduction in specificity. Gynecologists and oncologists in HE4 recognize the potential for monitoring therapy and progress of the disease.

Human epididymis protein 4; ROMA index; Ovarian cancer

nije evidentirano